BioNxt Provides Update on Cladribine Program for Multiple Sclerosis

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) has provided an update on its sublingual Cladribine drug formulation program aimed at treating Multiple Sclerosis (MS), a new patent for anticancer drug use in autoimmune neurodegenerative diseases, and recent investor relations activities.

BioNxt's sublingual Cladribine, targeting the MS market, offers benefits for patients with Dysphagia, common among MS sufferers. The company reported positive results from animal toxicity and pharmacokinetics studies earlier this year, with plans for a human bioequivalence study in early Q1 2025.

Furthermore, BioNxt announced a positive examination report from the European Patent Office for its sublingual delivery of anticancer drugs patent. The company plans to submit the patent in multiple jurisdictions, including the US, Canada, and China.

Additionally, BioNxt has confirmed the development of a sublingual drug delivery system for Myasthenia Gravis (MG), another condition where Dysphagia is prevalent. The company also outlined ongoing activities to engage consultants to manage investor relations and increase market liquidity.